• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体 α 的激活的分子机制由 WY14643 介导:一种新的配体识别和受体稳定模式。

Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.

机构信息

Institute of Physics of São Carlos, University of São Paulo, Avenida Trabalhador Sãocarlense 400, São Carlos, SP 13560-970, Brazil.

出版信息

J Mol Biol. 2013 Aug 23;425(16):2878-93. doi: 10.1016/j.jmb.2013.05.010. Epub 2013 May 21.

DOI:10.1016/j.jmb.2013.05.010
PMID:23707408
Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of a superfamily of nuclear transcription factors. They are involved in mediating numerous physiological effects in humans, including glucose and lipid metabolism. PPARα ligands effectively treat dyslipidemia and have significant antiinflammatory and anti-atherosclerotic activities. These effects and their ligand-dependent activity make nuclear receptors obvious targets for drug design. Here, we present the structure of the human PPARα in complex with WY14643, a member of fibrate class of drug, and a widely used PPAR activator. The crystal structure of this complex suggests that WY14643 induces activation of PPARα in an unusual bipartite mechanism involving conventional direct helix 12 stabilization and an alternative mode that involves a second ligand in the pocket. We present structural observations, molecular dynamics and activity assays that support the importance of the second site in WY14643 action. The unique binding mode of WY14643 reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering clues for improving the binding affinity and selectivity of ligand. We show that binding of WY14643 to PPARα was associated with antiinflammatory disease in a human corneal cell model, suggesting possible applications for PPARα ligands.

摘要

过氧化物酶体增殖物激活受体 (PPARs) 是核转录因子超家族的成员。它们参与介导人类的许多生理效应,包括葡萄糖和脂质代谢。PPARα 配体有效地治疗血脂异常,并具有显著的抗炎和抗动脉粥样硬化活性。这些作用及其配体依赖性活性使核受体成为药物设计的明显靶点。在这里,我们展示了人 PPARα 与 WY14643 复合物的结构,WY14643 是一种纤维酸类药物,也是广泛使用的 PPAR 激活剂。该复合物的晶体结构表明,WY14643 通过一种不寻常的双部分机制诱导 PPARα 的激活,该机制涉及常规的直接螺旋 12 稳定和另一种涉及口袋中第二个配体的替代模式。我们提出了结构观察、分子动力学和活性测定结果,支持了 WY14643 作用中第二个部位的重要性。WY14643 的独特结合模式揭示了核受体配体识别的新模式,并为配体设计提供了新的基础,为提高配体的结合亲和力和选择性提供了线索。我们表明,WY14643 与 PPARα 的结合与人类角膜细胞模型中的抗炎疾病有关,这表明 PPARα 配体可能有应用前景。

相似文献

1
Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.过氧化物酶体增殖物激活受体 α 的激活的分子机制由 WY14643 介导:一种新的配体识别和受体稳定模式。
J Mol Biol. 2013 Aug 23;425(16):2878-93. doi: 10.1016/j.jmb.2013.05.010. Epub 2013 May 21.
2
Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer.人源 PPARα-RXRα 异二聚体变构通讯的分子机制。
Proteins. 2010 Mar;78(4):873-87. doi: 10.1002/prot.22613.
3
Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.优化酶联免疫吸附测定法以筛选过氧化物酶体增殖物激活受体α的配体。
Immunopharmacol Immunotoxicol. 2009;31(3):459-67. doi: 10.1080/08923970902785246.
4
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.过氧化物酶体增殖物激活受体γ(PPARγ)配体结合域与新型部分激动剂复合的晶体结构:疏水口袋的一个新区域可用于药物设计。
J Med Chem. 2008 Dec 25;51(24):7768-76. doi: 10.1021/jm800733h.
5
Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.过氧化物酶体增殖物激活受体α/γ双重激动剂GL479的不同结合和识别模式
J Struct Biol. 2015 Sep;191(3):332-40. doi: 10.1016/j.jsb.2015.07.006. Epub 2015 Jul 14.
6
Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα.过氧化物酶体增殖物激活受体 α(PPARα)及其新型特异高效配体非诺贝特的分子缔合模型:SPPARMα 的结构基础。
Biochem Biophys Res Commun. 2018 May 5;499(2):239-245. doi: 10.1016/j.bbrc.2018.03.135. Epub 2018 Mar 22.
7
PPARα agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms.过氧化物酶体增殖物激活受体α激动剂 Wy14643 通过转录、转录后和翻译后机制抑制人内皮细胞中的组织蛋白酶 B。
Angiogenesis. 2013 Jan;16(1):223-33. doi: 10.1007/s10456-012-9314-9. Epub 2012 Oct 25.
8
PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.过氧化物酶体增殖物激活受体α激动剂可抑制巨噬细胞中骨桥蛋白的表达,并降低2型糖尿病患者的血浆水平。
Diabetes. 2007 Jun;56(6):1662-70. doi: 10.2337/db06-1177. Epub 2007 Mar 14.
9
Comparison of full-length versus ligand binding domain constructs in cell-free and cell-based peroxisome proliferator-activated receptor alpha assays.在无细胞和基于细胞的过氧化物酶体增殖物激活受体α检测中全长与配体结合域构建体的比较。
Anal Biochem. 2005 Apr 1;339(1):121-8. doi: 10.1016/j.ab.2005.01.007.
10
Stabilization of peroxisome proliferator-activated receptor alpha by the ligand.配体对过氧化物酶体增殖物激活受体α的稳定作用。
Biochem Biophys Res Commun. 2001 Oct 19;288(1):106-10. doi: 10.1006/bbrc.2001.5739.

引用本文的文献

1
Peroxisome proliferator-activated receptor alpha is an essential factor in enhanced macrophage immune function induced by angiotensin-converting enzyme.过氧化物酶体增殖物激活受体α是血管紧张素转换酶诱导巨噬细胞免疫功能增强的关键因素。
Cell Mol Immunol. 2025 Mar;22(3):243-259. doi: 10.1038/s41423-025-01257-y. Epub 2025 Feb 5.
2
Current Challenges in Monitoring Low Contaminant Levels of Per- and Polyfluoroalkyl Substances in Water Matrices in the Field.现场监测水基质中低浓度全氟和多氟烷基物质的当前挑战
Toxics. 2024 Aug 20;12(8):610. doi: 10.3390/toxics12080610.
3
The Peroxisome Proliferator-Activated Receptors of Ray-Finned Fish: Unique Structures, Elusive Functions.
《硬骨鱼类过氧化物酶体增殖物激活受体:独特的结构,难以捉摸的功能》。
Biomolecules. 2024 May 29;14(6):634. doi: 10.3390/biom14060634.
4
Novel 1,2,4-oxadiazole compounds as PPAR-α ligand agonists: a new strategy for the design of antitumour compounds.新型1,2,4-恶二唑化合物作为PPAR-α配体激动剂:抗肿瘤化合物设计的新策略。
RSC Med Chem. 2023 Jun 15;14(7):1377-1388. doi: 10.1039/d3md00063j. eCollection 2023 Jul 20.
5
Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation.靶向替代维生素 E 代谢物结合位点可实现非典型 PPARγ 调节。
J Am Chem Soc. 2023 Jul 12;145(27):14802-14810. doi: 10.1021/jacs.3c03417. Epub 2023 Jun 29.
6
Atractylodin Ameliorates Colitis via PPARα Agonism.苍术素通过激活过氧化物酶体增殖物激活受体 α 改善结肠炎。
Int J Mol Sci. 2023 Jan 2;24(1):802. doi: 10.3390/ijms24010802.
7
Macakurzin C Derivatives as a Novel Pharmacophore for Pan-Peroxisome Proliferator-Activated Receptor Modulator.马卡库尔津C衍生物作为一种新型的泛过氧化物酶体增殖物激活受体调节剂的药效基团。
Biomol Ther (Seoul). 2023 May 1;31(3):312-318. doi: 10.4062/biomolther.2022.097. Epub 2022 Nov 16.
8
Lipid Messenger Phosphatidylinositol-4,5-Bisphosphate Is Increased by Both PPARα Activators and Inhibitors: Relevance for Intestinal Cell Differentiation.脂质信使磷脂酰肌醇-4,5-二磷酸被过氧化物酶体增殖物激活受体α(PPARα)激活剂和抑制剂均上调:与肠细胞分化的相关性
Biology (Basel). 2022 Jun 30;11(7):997. doi: 10.3390/biology11070997.
9
Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα.介导过氧化物酶体脂肪酸β-氧化的 PPARα 调节机制。
Int J Mol Sci. 2021 Aug 20;22(16):8969. doi: 10.3390/ijms22168969.
10
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.糖尿病相关非酒精性脂肪性肝病和肝纤维化的治疗靶点、新型药物及给药系统
Adv Drug Deliv Rev. 2021 Sep;176:113888. doi: 10.1016/j.addr.2021.113888. Epub 2021 Jul 24.